Muhammad Bilal Abid, MD, MRCP, highlights the clinical takeaways from a study examining the effectiveness of a third SARS-CoV-2 mRNA vaccine dose among patients treated with hematopoietic cell transplantation, CAR T-cell therapy, and bispecific antibodies.
Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.
The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation or cellular therapy following initial failure of seroconversion after the first 2 vaccine doses.
Muhammad Bilal Abid, MD, MRCP, discusses clinical takeaways regarding the standard use of a third SARS-CoV-2 mRNA vaccine dose among patients treated with hematopoietic cell transplantation, CAR T-cell therapy, and bispecific T-cell engagers.
Muhammad Bilal Abid, MD, MRCP, discusses the efficacy of a third COVID-19 vaccine dose after hematopoietic cell transplantation in patients with hematologic malignances.
